Findings

What do systematic reviews say?

7 questions · 7 findings · 5 reviews · Vascular

Sort:Best matchNewest Highest certainty Download CSV

No studies found 2 · 28.6%GRADE not reported 0 · 0%Very low 0 · 0%Low 1 · 14.3%Moderate 4 · 57.1%High 0 · 0%

Vitamin K antagonists vs placebo or no thromboprophylaxis

1‐year overall mortality · ambulatory cancer patients receiving chemotherapy

The review found no eligible studies for this question.

1 finding from 1 review

Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Vitamin K antagonists vs active control

1‐year overall mortality · ambulatory cancer patients receiving chemotherapy

The review found no eligible studies for this question.

1 finding from 1 review

Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Fondaparinux plus vitamin K antagonist vs usual care

All‐cause mortality · people > 18 years of age with a diagnosed deep vein thrombosis

Fondaparinux plus vitamin K antagonist showed no clear difference in all‐cause mortality compared with standard therapy (moderate certainty).

1 finding from 1 review

Pentasaccharides for the treatment of deep vein thrombosis 2017 · Cochrane Headline outcomes only
RR 0.93 [0.45, 1.91]
2 studies · 2645 participants
Moderate

Intervention not reported

Mortality · patients with venous thromboembolism

The intervention showed no clear difference in mortality (moderate certainty).

1 finding from 1 review

Duration of treatment with vitamin K antagonists in symptomatic venous thromboembolism 2014 · Cochrane Headline outcomes only
RR 0.69 [0.35, 1.34]
4 studies · 1049 participants
Moderate

Direct thrombin inhibitors vs vitamin K antagonist (VKA)

All‐cause Mortality events in TKR combined doses · patients with prevention of venous thromboembolism following total hip or knee replacement

Direct thrombin inhibitors showed no clear difference in all‐cause Mortality events in TKR combined doses compared with vitamin K antagonists (low certainty).

1 finding from 1 review

Direct thrombin inhibitors versus vitamin K antagonists or low molecular weight heparins for prevention of venous… 2010 · Cochrane Headline outcomes only
OR 1.62 [0.57, 4.58]
3 studies · 5243 participants
Low

Direct thrombin inhibitors vs low molecular weight heparin

All‐cause Mortality events · patients with prevention of venous thromboembolism following total hip or knee replacement

Direct thrombin inhibitors probably leads to higher all‐cause Mortality events compared with low molecular weight heparins (moderate certainty).

1 finding from 1 review

Direct thrombin inhibitors versus vitamin K antagonists or low molecular weight heparins for prevention of venous… 2010 · Cochrane Headline outcomes only
OR 2.06 [1.1, 3.87]
11 studies · 22065 participants
Moderate

Low molecular weight heparin vs vitamin K antagonist (VKA)

Mortality (treatment duration 3 months) · patients with symptomatic VTE requiring long term treatment (3 months) for symptomatic VTE

LMWH showed no clear difference in mortality (treatment duration 3 months) compared with VKA (moderate certainty).

1 finding from 1 review

Vitamin K antagonists versus low‐molecular‐weight heparin for the long term treatment of symptomatic venous… 2017 · Cochrane Headline outcomes only
Peto OR 1.08 [0.75, 1.56]
16 studies · 3299 participants
Moderate